Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

Maria Isabel Del Olmo-Garcia; Stefan Prado-Wohlwend; Alexia Andres; Jose M Soriano; Pilar Bello; Juan Francisco Merino-Torres

doi:10.3390/biomedicines9121810

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

Biomedicines. 2021 Dec 1;9(12):1810. doi: 10.3390/biomedicines9121810.

Authors

Maria Isabel Del Olmo-Garcia^{1

2}, Stefan Prado-Wohlwend³, Alexia Andres¹, Jose M Soriano^{2

4}, Pilar Bello³, Juan Francisco Merino-Torres^{1

2}

Affiliations

¹ Endocrinology and Nutrition Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain.
² Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, University of Valencia-Health Research Institute La Fe, 46026 Valencia, Spain.
³ Nuclear Medicine Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain.
⁴ Food & Health Lab, Institute of Materials Science, University of Valencia, 46980 Valencia, Spain.

Abstract

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.

Keywords: 68Ga PET; LU-DOTA-TATE; neuroendocrine neoplasms; peptide receptor radionuclide therapy; somatostatin analogues; somatostatin antagonists; somatostatin receptors.

Publication types

Review